Atomo In The News

Empowering people to enjoy healthier, more informed lives through fast, accurate point-of-care testing.

Access to self-testing is one of the pillars of Australia’s HIV prevention strategy.

June 8, 2022

An article from The Pharmacy Guild of Australia on how access to self-testing is a key component in the prevention strategy for HIV in Australia

Education for pharmacists on HIV self-testing

March 31, 2022

An article from The Pharmacy Guild of Australia on Atomo’s partnership with GuildEd designed to provide education for pharmacists on HIV self-testing.

COVID-19 Sparks At-Home HIV Test Revolution

November 2, 2021

An article from political journalist Tom McIlroy in The Financial Review regarding the way in which the approach towards self testing of COVID-19 has revolutionised the way in which the HIV self testing market operates.

Equity ASA Podcast

20 September, 2021

Co-founder and Managing Director, John Kelly, chats with Phil Muscatello on The Equity ASA podcast, produced for the Australian Shareholders’ Association.

Atomo Diagnostics (ASX:AT1) and Viatris to Support HIV Self-Test Supply

April 29, 2021

An article by Carolyn Rebeiro in The Market Herald on our support for Unitaid’s quest to expand access to HIV self-test supply to low- and middle-income countries.

Experts call for TGA-approved rapid COVID-19 tests to be used in Australia

March 22, 2021

Our MD, John Kelly spoke to ABC News about the need for rapid antibody and antigen tests to be used in Australia.

Escrow: Here’s why it’s worth watching and which stocks are releasing shares soon

March 11, 2021

Stockhead lists Atomo Diagnostics as a stock to watch.

Is Atomo Diagnostics Finally Ready to Take Off?

March 9, 2021

MD John Kelly spoke to Alan Kohler about our point-of-care rapid tests.

The Atomo Diagnostics (ASX:AT1) share price is popping 7% today

March 2, 2021

The Motley Fool talks about Atomo Diagnostics’ share price rise.

Atomo gains rights to rapid antigen test

October 1, 2020

An article by Biotech Dispatch on our expanded partnership with Access Bio to launch a rapid antigen test in Australia, New Zealand and India.

"Game changing” deal for Aussie biotech Atomo

September 30, 2020

Our MD, John Kelly sat down with Ausbiz to discuss our rapid antigen test deal with Access Bio which will enable screening for acute infection and exposure at the same time.

Why the Atomo (ASX:AT1) share price is moving higher today

September 29, 2020

An article by Aaron Teboneras of the Motley Fool on our expanded a partnership with Access Bio to launch a rapid antigen test in Australia, New Zealand and India.

Re-imagining diagnostics.